WR Wealth Planners’s BioMarin Pharmaceuticals BMRN Stock Holding History

WR Wealth Planners’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-693	Closed	-$48.7K	–	1117
2024 Q3	$48.7K	Hold	693	–	–	0.01%	343
2024 Q2	$57.1K	Hold	693	–	–	0.02%	312
2024 Q1	$60.5K	Buy	+693	New	+$62K	0.02%	306
2023 Q4	–	Sell	-693	Closed	-$61.3K	–	252
2023 Q3	$61.3K	Hold	693	–	–	0.02%	294
2023 Q2	$60.1K	Hold	693	–	–	0.02%	296
2023 Q1	$67.4K	Buy	+693	New	+$71.8K	0.03%	282

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

EIM

Elliott Investment Management West Palm Beach, Florida $20.1B AUM 60.76% 1-Year Est. Return

WR Wealth Planners's BMRN Position: Q4 2024 in Review

WR Wealth Planners sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2024, closing a stake of 693 shares — an estimated $48.7K sold.

WR Wealth Planners first reported a position in BMRN in Q1 2023 and held it in 6 quarters. The position peaked at $67.4K in Q1 2023. 544 funds tracked by Wall St. Rank hold BMRN as of Q4 2024.

WR Wealth Planners reported no remaining BioMarin Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
WR Wealth Planners sold 693 BioMarin Pharmaceuticals shares in Q4 2024, an estimated $48.7K.
WR Wealth Planners first reported a position in BioMarin Pharmaceuticals in Q1 2023 and held it in 6 quarters.
WR Wealth Planners's BioMarin Pharmaceuticals position peaked at $67.4K in Q1 2023.
544 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2024.

Based on WR Wealth Planners's 13F filing for Q4 2024, filed 5 Feb 2025.